4:46 PM ET
8-K
Clinical Trial Data
Phathom Pharmaceuticals Clinical Trial Data
Phathom Pharmaceuticals has initiated patient screening for pHalcon-NERD-302, a registrational Phase 3 study evaluating VOQUEZNA (vonoprazan) as an as-needed treatment for Non-Erosive Gastroesophageal Reflux Disease (NERD). The multicenter study aims to enroll approximately 500 adults across 80 U.S. sites, with topline results expected in the first quarter of 2028.